ReviewFrontiers in endocrinology2025
The strategic role of lipidomics in biomarker identification and diagnosis of gynecological diseases.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development.Molecular biology reports · 2026Review
- Advancing human ovarian biology in tandem with clinical care: considerations for collecting ovarian tissue for research after oophorectomy for tissue cryopreservation.Frontiers in endocrinology · 2026Review
- Uterine morphology in normogonadotropic anovulation: a comparative study of polycystic ovary syndrome and hypothalamic-pituitary-ovarian dysfunction.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipidomics, an emerging field in medical research, has deepened our understanding of lipid metabolism, signal transduction pathways, and intercellular communication through qualitative and quantitative analyses of patient lipid profiles. It has closely linked these biological processes to the occurrence and progression of diseases, opening new avenues of research and providing new perspectives on the diagnosis, treatment, and personalized medicine of clinical diseases. Gynecological diseases have a profound impact on women's health but often face challenges due to delayed diagnosis and inadequate treatment options. Lipids play a crucial role in regulating cell proliferation, differentiation, and signal transduction, making them significant in the occurrence and development of gynecological diseases. The technological progress in lipidomics has greatly advanced our comprehension of lipid metabolism and biochemical mechanisms in these diseases, while also offering new technical pathways for identifying potential biomarkers. Thus, this review summarized the application of lipidomics in gynecological diseases, especially those with high incidence rates such as ovarian cancer, cervical cancer, and endometriosis, to assesses its application potential in the diagnosis, prognosis monitoring, and development of new treatment strategies for gynecological diseases, and discusses its future development trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.